Patents Examined by Jessica Soto-Rodriguez
  • Antibodies to PMEL17 and conjugates thereof
    Patent number: 11779649
    Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 10, 2023
    Assignee: Novartis AG
    Inventors: Matthew Burger, Joseph Anthony D'Alessio, Tony Fleming, Vivek Rauniyar, Eusebio Manchado Robles, Christian Kunz, Markus Waldhuber
  • Anti-Siglec-7 antibodies for the treatment of cancer
    Patent number: 11773162
    Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: October 3, 2023
    Assignee: Allakos, Inc.
    Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
  • Antibodies and variants thereof against TIGIT
    Patent number: 11708410
    Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes TIGIT. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 25, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Xinpo Jiang, Shuai Yang, Chuan-Chu Chou
  • T-cell receptor recognizing SSX2 antigen
    Patent number: 11649270
    Abstract: A T cell receptor (TCR) capable of specifically binding to a short peptide KASEKIFYV derived from an AFP antigen. The antigen short peptide KASEKIFYV can form a complex with HLA A0201 and be presented together with same to the cell surface. A nucleic acid molecule encoding the TCR, a vector comprising the nucleic acid molecule, and a cell that transduces the TCR.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: May 16, 2023
    Assignee: XLIFESC, LTD.
    Inventors: Yi Li, Jing Hu, Jun Li, Hanli Sun